CN115005447B - 低聚古罗糖醛酸在制备抗疲劳产品中的应用 - Google Patents
低聚古罗糖醛酸在制备抗疲劳产品中的应用 Download PDFInfo
- Publication number
- CN115005447B CN115005447B CN202210680622.8A CN202210680622A CN115005447B CN 115005447 B CN115005447 B CN 115005447B CN 202210680622 A CN202210680622 A CN 202210680622A CN 115005447 B CN115005447 B CN 115005447B
- Authority
- CN
- China
- Prior art keywords
- fatigue
- acid
- medicament
- preparing
- oligoguluronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002929 anti-fatigue Effects 0.000 title claims abstract description 12
- 239000002253 acid Substances 0.000 title claims description 22
- 238000002360 preparation method Methods 0.000 title description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229920002527 Glycogen Polymers 0.000 claims abstract description 16
- 229940096919 glycogen Drugs 0.000 claims abstract description 16
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 15
- 239000004310 lactic acid Substances 0.000 claims abstract description 15
- 210000002966 serum Anatomy 0.000 claims abstract description 10
- 238000011084 recovery Methods 0.000 claims abstract description 6
- 210000002027 skeletal muscle Anatomy 0.000 claims abstract description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000004202 carbamide Substances 0.000 claims abstract description 4
- 230000002440 hepatic effect Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 10
- IAJILQKETJEXLJ-SQOUGZDYSA-N L-guluronic acid Chemical compound O=C[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O IAJILQKETJEXLJ-SQOUGZDYSA-N 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- -1 oligosaccharide compound Chemical class 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- AEMOLEFTQBMNLQ-BZINKQHNSA-N D-Guluronic Acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@@H](O)[C@H]1O AEMOLEFTQBMNLQ-BZINKQHNSA-N 0.000 abstract description 8
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 abstract description 6
- 230000009182 swimming Effects 0.000 description 25
- 206010016256 fatigue Diseases 0.000 description 24
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 10
- 210000003205 muscle Anatomy 0.000 description 10
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 8
- CNNRPFQICPFDPO-UHFFFAOYSA-N octacosan-1-ol Chemical group CCCCCCCCCCCCCCCCCCCCCCCCCCCCO CNNRPFQICPFDPO-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 229960002666 1-octacosanol Drugs 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037080 exercise endurance Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种低聚古罗糖醛酸在制备抗疲劳产品中的应用,所述的产品为:(1)增加骨骼肌的运动耐受力的产品;(2)加快机体疲劳恢复的产品;(3)抗疲劳产品;(4)降低运动后血清中乳酸和尿素含量的产品;或(5)增加机体肝糖原和肌糖原储备的产品。
Description
技术领域
本发明属于生物技术领域,具体的,涉及一种低聚古罗糖醛酸在制备抗疲劳产品中的应用。
背景技术
疲劳是机体复杂的生理生化变化过程,是指脑力或体力到达一定阶段时必然出现的一种正常的生理现象。它既标志着机体原有工作能力的暂时下降,又可能是机体发展到疾病状态的先兆。疲劳的出现,可引起运动能力降低、工作效率降低、差错事故增多。疲劳发生后如果得不到及时恢复,逐渐积累,还会导致“过劳”,使机体发生内分泌紊乱、免疫力下降,甚至出现器质性疾病,威胁人类健康。
机体疲劳可以通过休息、睡眠以及物理方法消除,另外还可以通过补充营养物质和药物疗法来实现抗疲劳的作用。一些支链氨基酸(BCAA)包括亮氨酸和异亮氨酸等,在肌肉中分解代谢,易被氧化为机体提供能量,对维持人脑的正常活动以及延缓和消除运动性疲劳有重要作用。另外,还有肌酸、B族维生素、维生素C、维生素E、维生素A、胡萝卜素、微量元素硒、铜、锌和金属硫蛋白等也可以提高机体的代谢作用,延缓疲劳的发生。近年来,疲劳作为亚健康症状也越来越备受人们的关注,抗疲劳即延缓疲劳的产生和/或促进疲劳的消除,目前已成为运动医学上研究的一个热点问题。
低聚古罗糖醛酸是一种由海洋褐藻中提取分离获得的胞间多糖,是由L-古罗糖醛酸(L-Guluronic acid,G)通过α-1,4-糖苷键连接组成的线型化合物。目前,国内外有文献报道低聚古罗糖醛酸具有抗氧化、免疫调节、调节粘膜蛋白功能等多种生物学活性,但关于低聚古罗糖醛酸在抗疲劳方面的研究和应用尚未见报导。
发明内容
本发明首先涉及低聚古罗糖醛酸或其盐在制备如下产品中的应用:
(1)增加骨骼肌的运动耐受力的产品;
(2)加快机体疲劳恢复的产品;
(3)抗疲劳产品;
(4)降低运动后血清中乳酸和尿素含量的产品;
(5)增加机体肝糖原和肌糖原储备的产品;
所述的产品为食品或药品,
所述的低聚古罗糖醛酸或其盐的结构如下式所示,其分子骨架为L-古罗糖醛酸(G)通过α-(1,4)-糖苷键连接形成的线性寡糖化合物,重均分子量范围为0.3kD~15kD;
式中,R=H或Li,Na,K,Ca,Mg,n≤60。
所述的食品或药品为口服剂型,包括但不限于片剂、冲剂、口服液;
所述的食品或药品中包括,有效量的所述低聚古罗糖醛酸或其盐,以及必要的辅料。
本发明的有益效果在于,
(1)本发明阐明低聚古罗糖醛酸可以较好增加骨骼肌的运动耐受力,加快疲劳机体的恢复,具有很好的抗疲劳的作用。
(2)本发明涉及的低聚古罗糖醛酸化合物具备低分子量酸性寡糖的优点,不仅水溶性强、容易吸收,而且来源丰富、作用机理独特,具有广阔的产业化开发应用前景。
附图说明
图1、低分子量古罗糖醛酸(LG)(盐)的化学结构。
具体实施方式
本发明通过实验首次证明低分子量古罗糖醛酸可有效地延长力竭小鼠的游泳时间,显著降低血乳酸和血清尿素氮的水平,并明显提高力竭小鼠的肝糖原和肌糖原的含量;因此可用于预防或者改善疲劳症状。
本发明中的低分子量古罗糖醛酸可以从海带、巨藻、墨角藻、泡叶藻、昆布或绳藻相关褐藻中提取得到的褐藻胶经过分级和降解而得,也可以经过化学方法合成而得。
所述低分子量古罗糖醛酸(LG)的糖残基之间均由α-1,4-D-甘露糖醛酸组成,其结构式如下:
式中,R=H或Li,Na,K,Ca,Mg等金属阳离子,n≤80,优选为25~50;
所述低分子量古罗糖醛酸的重均分子量范围为0.3kD~15kD,优选为5kD~10kD。
实施例1:低聚古罗糖醛酸(LG)对力竭小鼠游泳时间的影响
测定小鼠持续运动到力竭的时间可以反映机体的耐力。
采用小鼠游泳力竭模型,实验步骤如下:
(1)小鼠连续灌胃2周,灌胃药物及剂量为:阳性药物选用二十八烷醇(10mg/kg),低聚古罗糖醛酸盐分为低剂量组(25mg/kg),中剂量组(50mg/kg),高剂量组(100mg/kg);灌胃每天1次;LG的盐型为钠盐或镁盐,重均分子量为8kD。
(2)于最后一次处理半小时后,将小鼠尾部负重3%体重的铅丝,置于50cm×50cm×40cm的游泳池中游泳,水温30±1℃,记录小鼠开始游泳至游不动力竭沉入水面下8秒且不能浮出水面为止的时间,即小鼠游泳力竭时间。
结果如表1所示:力竭游泳时间与LG存在线性剂量效应关系,高剂量组相对于空白组力竭游泳时间增加最多,为63.5%,中等剂量组增加39.2%,二十八烷醇组増加了67.5%,表明LG高剂量组和中剂量组能够提高小鼠的运动耐力,具有抗疲劳作用,镁盐相比于钠盐效果更为理想。
表1 LG对小鼠负重游泳时间的影响
**p<0.01(与模型组比较),*p<0.05(与模型组比较)。
实施例2:低聚古罗糖醛酸(LG)对力竭小鼠血乳酸(BLA)和血清尿素氮(BUN)的影响
通常通过测定引起疲劳的生化指标,能够观察疲劳的出现及发展过程。当小鼠机体长时间不能通过糖、脂肪分解代谢获得足够多的能量时,蛋白质与氨基酸分解代谢便会加强,而且核苷酸的代谢也随之加快,这条代谢途径的最终产物都生成尿素。血尿素产生得越少,说明小鼠机体耐力越强,越能承受运动负荷。
血乳酸是在缺氧条件下糖酵解的产物,随着糖酵解速度的加快,肌肉中乳酸的含量不断累积,引起细胞pH值下降,产生一系列生化变化,进而导致疲劳。肌肉中积累越多的乳酸,疲劳的表现程度就越严重。
采用小鼠游泳力竭模型,实验步骤如下:
(1)小鼠连续灌胃2周后,阳性药物选用二十八烷醇(10mg/kg),低聚古罗糖醛酸盐分为低剂量组(25mg/kg),中剂量组(50mg/kg),高剂量组(100mg/kg);灌胃每天1次;LG的盐型为镁盐,重均分子量为8kD。
(2)于最后一次处理半小时后,尾部静脉取血,测定游泳前血尿素氮(BUN)、血乳酸(BLA)含量,将小鼠尾部负重3%体重的铅丝,置于50×50×40的游泳池中游泳,水温30±1℃,游泳1小时后取出小鼠,去除负重;
(3)安静15min后眼球取血,测定小鼠血尿素氮(BUN)、血乳酸(BLA)含量。
结果如表2,可见,
(1)游泳前各组血清尿素氮差异不明显,游泳后各组血清尿素氮含量明显增加。游泳后,与模型组相比,LG中剂量和高剂量组以及二十八烷醇组血清尿素氮显著低于模型组,这说LG能减少运动小鼠体内血清尿素氮的积累。
(2)游泳前各组血乳酸含量差异不明显,游泳后各组血乳酸含量明显增加。且模型组血乳酸含量明显高于LG中高剂量组和二十八烷醇组,说明LG能减少小鼠运动后体内血乳酸积累,加快机体的恢复。
表2 LG对小鼠血清尿素氮(BUN)和血乳酸(BLA)的影响
*p<0.05(与模型组比较)。
实施例3:低聚古罗糖醛酸(LG)对力竭小鼠肝糖原和肌糖元的影响
生物机体内糖原的储备与运动耐力呈正相关。运动时间增加时,会大量消耗肌糖原,使生物机体运动能力降低,出现疲劳,同时增加了对于血糖的摄取量,当摄取速度大于肝糖原的分解速度时,血糖水平降低。因为血糖供能给中枢神经***,血糖降低会引起中枢神经***动力不足,从而导致全身性疲劳。
采用小鼠游泳力竭模型,实验步骤如下:
(1)小鼠连续灌胃2周后,阳性药物选用二十八烷醇(10mg/kg),低聚古罗糖醛酸盐分为低剂量组(25mg/kg),中剂量组(50mg/kg),高剂量组(100mg/kg);灌胃每天1次;LG的盐型为镁盐,重均分子量为8kD。
(2)于最后一次处理半小时后,将小鼠尾部负重3%体重的铅丝,置于50×50×40的游泳池中游泳,水温30±1℃,游泳1小时后取出小鼠,去除负重;
(3)眼球取血后,立即处死,取出肝脏和后腿肌肉,分别测定肝糖原和肌糖原含量。
实验结果见表3,结果表明:中、高剂量组和二十八烷醇组的肝糖原和肌糖原明显高于空白组,说明中、高剂量组的LG可以增加肝糖原和肌糖原含量,而糖原可以直接分解成葡萄糖进入血液,通过血液循环供其他组织利用。因此,中、高剂量组的LG可以延缓和抵御疲劳的发生。
表3 LG对小鼠肝糖原和肌糖原的影响
*p<0.05(与模型组比较),**p<0.01(与模型组比较);#p<0.05(与阳性药物比较)。
上述实验结果表明,低聚古罗糖醛酸可以较好增加骨骼肌的运动耐受力,加快疲劳机体的恢复抗疲劳的作用。该低聚古罗糖醛酸可以作为一种天然保健品或者药物用于疲劳病症的预防和治疗。该制品来源于海洋海藻,具有资源丰富,易于产业化,且安全高等优点,在抗疲劳方面具有广阔的市场和应用前景。本发明将为海洋海藻的高值化利用提供借鉴意义和启示。
最后需要说明的是,以上实施例仅用于帮助本领域技术人员理解本发明的实质,不用于限定本发明的保护范围。
Claims (5)
1.低聚古罗糖醛酸或其盐的如下应用:
(1)制备增加骨骼肌的运动耐受力的药物;
(2)制备加快机体疲劳恢复的药物;
(3)制备抗疲劳药物;
(4)制备降低运动后血清中乳酸和尿素含量的药物;
(5)制备增加机体肝糖原和肌糖原储备的药物;
所述的低聚古罗糖醛酸或其盐的结构如下式所示,其分子骨架为L-古罗糖醛酸(G)通过α-(1,4)-糖苷键连接形成的线性寡糖化合物,重均分子量范围为5~10kD;
式中,R=H或Li,Na,K,Ca,Mg;n≤75。
2.根据权利要求1所述的应用,其特征在于,式中,R为Mg,n为25~50
3.根据权利要求1或2所述的应用,其特征在于,所述的药物为口服剂型。
4.根据权利要求3所述的应用,其特征在于,所述的药物为片剂或冲剂。
5.根据权利要求1或2所述的应用,其特征在于,所述的药物中包括,有效量的所述低聚古罗糖醛酸或其盐,以及必要的辅料。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210680622.8A CN115005447B (zh) | 2022-06-16 | 2022-06-16 | 低聚古罗糖醛酸在制备抗疲劳产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210680622.8A CN115005447B (zh) | 2022-06-16 | 2022-06-16 | 低聚古罗糖醛酸在制备抗疲劳产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115005447A CN115005447A (zh) | 2022-09-06 |
CN115005447B true CN115005447B (zh) | 2024-02-06 |
Family
ID=83075441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210680622.8A Active CN115005447B (zh) | 2022-06-16 | 2022-06-16 | 低聚古罗糖醛酸在制备抗疲劳产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115005447B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518897A (zh) * | 2003-09-01 | 2004-08-11 | 中国海洋大学 | 一种组合低聚糖及其制备方法和应用 |
CN101325973A (zh) * | 2005-10-06 | 2008-12-17 | Ntnu技术转让公司 | 寡聚糖醛酸盐用于治疗粘液高粘度的用途 |
CN103948611A (zh) * | 2014-03-31 | 2014-07-30 | 青岛海洋生物医药研究院股份有限公司 | 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用 |
CN104666327A (zh) * | 2015-01-14 | 2015-06-03 | 中国海洋大学 | 低聚甘露糖醛酸及其衍生物在制备抗疲劳和抗肌萎缩的药物和保健品中的应用 |
CN105395563A (zh) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用 |
CN110652517A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 褐藻胶寡糖二酸的组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100501584B1 (ko) * | 2000-02-03 | 2005-07-18 | (주)케이비피 | 저분자 폴리만유로네이트의 제조방법, 혈청지질개선제로서의 이의 신규 용도 및 이를 함유하는 기능성식품 및 건강 보조 식품 |
WO2009142770A2 (en) * | 2008-05-23 | 2009-11-26 | The Regents Of The University Of California | Compositions and methods for generating musculoskeletal tissue |
-
2022
- 2022-06-16 CN CN202210680622.8A patent/CN115005447B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518897A (zh) * | 2003-09-01 | 2004-08-11 | 中国海洋大学 | 一种组合低聚糖及其制备方法和应用 |
CN101325973A (zh) * | 2005-10-06 | 2008-12-17 | Ntnu技术转让公司 | 寡聚糖醛酸盐用于治疗粘液高粘度的用途 |
CN103948611A (zh) * | 2014-03-31 | 2014-07-30 | 青岛海洋生物医药研究院股份有限公司 | 低聚古罗糖醛酸盐在制备防治帕金森症药物或制品中的应用 |
CN104666327A (zh) * | 2015-01-14 | 2015-06-03 | 中国海洋大学 | 低聚甘露糖醛酸及其衍生物在制备抗疲劳和抗肌萎缩的药物和保健品中的应用 |
CN105395563A (zh) * | 2015-12-11 | 2016-03-16 | 青岛海洋生物医药研究院股份有限公司 | 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用 |
CN110652517A (zh) * | 2018-06-29 | 2020-01-07 | 上海绿谷制药有限公司 | 褐藻胶寡糖二酸的组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN115005447A (zh) | 2022-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100502692C (zh) | 一种体力恢复保健食品及其制备方法 | |
CN101889679B (zh) | 一种具有解酒保肝作用的组合物及其在食品、保健食品中的应用 | |
CN1927383B (zh) | 迅速降低氧化应激的复方制剂及其制备方法 | |
CN104223107B (zh) | 一种护肝解酒排毒的保健品 | |
CN102448452A (zh) | 用于支持糖尿病治疗的包含α-酮酸的膳食补充剂 | |
CN103251054B (zh) | 一种抗疲劳保健食品组合物及其制备方法 | |
US6740502B2 (en) | Method for preparing zinc-oligopeptide easily absorbable by the human body | |
CN107581599A (zh) | 一种供产妇自然分娩时食用含短肽的特殊膳食用食品配方 | |
CN102406115A (zh) | 一种防治心脑血管疾病的天然功能食品 | |
CN103446174A (zh) | 低聚甘露糖醛酸在制备预防和治疗酒精性肝损伤的药物、保健品或饮食补充剂中的应用 | |
CN104757560A (zh) | 一种谷胱甘肽酵母酶解组合物及其制备方法 | |
CN115005447B (zh) | 低聚古罗糖醛酸在制备抗疲劳产品中的应用 | |
CN104666327B (zh) | 低聚甘露糖醛酸及其衍生物在制备抗疲劳和抗肌萎缩的药物和保健品中的应用 | |
CN101336723B (zh) | 一种用于缓解体力疲劳的保健食品 | |
CN101352236B (zh) | 大果沙棘复合抗疲劳粉末及其制备方法 | |
CN105395563A (zh) | 低聚古罗糖醛酸及其衍生物在制备预防和治疗高脂血症及其并发症的药物和保健品中的应用 | |
CN101081281A (zh) | 用于提高人体免疫力及抗疲劳的抵抗力胶囊及其制备方法 | |
CN1597703A (zh) | 低分子海藻酸钾及其应用 | |
CN107325163B (zh) | 黄芪种子蛋白及其在抗运动疲劳功能食品中的应用 | |
CN103330118A (zh) | 减肥药物 | |
KR100483328B1 (ko) | 피로 회복 기능을 가지는 조성물 및 그 제조 방법과 이를이용한 피로 회복제 | |
CN1861099B (zh) | 蛇油软胶囊 | |
CN110743002A (zh) | 一种具有抗疲劳功能的海参饮品及其制备方法 | |
CN112471514B (zh) | 一种促进运动后体能恢复的食品组合物 | |
CN1759706A (zh) | 一种营养奶茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |